<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743206</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201902662</org_study_id>
    <secondary_id>OCR39724</secondary_id>
    <nct_id>NCT04743206</nct_id>
  </id_info>
  <brief_title>Airway Clearance for Pediatric and Adult Cystic Fibrosis Patients Using a Portable Intra-Pulmonary Percussion Device</brief_title>
  <official_title>Airway Clearance for Pediatric and Adult Cystic Fibrosis Patients Using a Portable Intra-Pulmonary Percussion Device (PIAPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study where the investigators aim to compare initial use of the standard&#xD;
      airway clearance device (SACD) with subsequent use of a Portable Intra-Pulmonary Percussion&#xD;
      Device (PIAPD) in patients with cystic fibrosis ages 6 -21 years. The primary hypothesis is&#xD;
      that there is no effect of PIAPD on FEV1 2 hours after use, there is no effect on perception&#xD;
      of effort and efficacy for the PIAPD. If both are equally effective, the latter device&#xD;
      provides an alternative that is both cheaper and portable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a pilot study where the investigators aim to compare initial use of the standard airway clearance device (SACD) with subsequent use of a PIAPD in patients with stable cystic fibrosis ages 6 -21 years. The primary hypothesis (Stated as Null) being that there is no effect of PIAPD on FEV1 2 hours after use, there is no effect on perception of effort and efficacy for the PIAPD.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the number of cystic fibrosis patients perception of breathing effort and device use</measure>
    <time_frame>14 days</time_frame>
    <description>The number of cystic fibrosis patients perception of their breathing effort and device use</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>PIAPD-Portable Internal Airway Percussion device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There will be an Inpatient Arm and Outpatient Arm using the Smart One® portable home spirometer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SACD-Standard Airway Clearance device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There will be an Inpatient Arm and Outpatient Arm using the SACD.&#xD;
A large majority of patients will be using VEST therapy as their standard of care airway clearance. A few might be using an Intrapulmonary Percussion Device that uses a mechanism different from the device the study will be testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Airway Clearance device</intervention_name>
    <description>A large majority of our patients will be using VEST therapy as their standard of care airway clearance</description>
    <arm_group_label>SACD-Standard Airway Clearance device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portable Internal Airway Percussion device</intervention_name>
    <description>Smart One® portable home spirometer</description>
    <arm_group_label>PIAPD-Portable Internal Airway Percussion device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 6-21 years&#xD;
&#xD;
          -  Cystic fibrosis stable by physician assessment&#xD;
&#xD;
          -  Assents to forego additional experimental treatments during the study&#xD;
&#xD;
          -  Currently using and familiar with airway clearance therapy for treatment of cystic&#xD;
             fibrosis&#xD;
&#xD;
          -  Participant (or parent or legal guardian if the participant is a minor) is willing to&#xD;
             provide -----InformedConsent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FEV1 &lt; 40% predictive&#xD;
&#xD;
          -  Pneumothorax&#xD;
&#xD;
          -  Hemoptysis&#xD;
&#xD;
          -  COVID-19 diagnosis within last 14 days&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would interfere with the study&#xD;
             conduct or the safety of the participant&#xD;
&#xD;
               -  Additional Exclusion Criteria: Outpatient Arm (in addition to general exclusion&#xD;
                  criteria above) Decrease in FEV1 &gt; 10% from baseline over last 12 months&#xD;
                  Antibiotic Initiation for acute CF exacerbation Hospitalization for CF&#xD;
                  Exacerbation&#xD;
&#xD;
               -  Additional Exclusion Criteria: Inpatient Arm (in addition to general exclusion&#xD;
                  criteria above) Failure to increase FEV1 &gt; 10 % from initial PFTs on admission by&#xD;
                  day 9 of hospitalization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Delgado Villalta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Hosford</last_name>
    <phone>3523010676</phone>
    <email>Jennifer.Hosford@peds.ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UF Medical Plaza Pulmonary Clinic</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Hosford</last_name>
      <phone>352-301-0676</phone>
      <email>Jennifer.Hosford@peds.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>SILVIA</last_name>
    </contact_backup>
    <investigator>
      <last_name>DELGADO VILLALTA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Airway Clearance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

